A man in Germany scheduled his own euthanasia. At the age of 41, he had been diagnosed with early-onset Parkinson's. By 51, he was bedridden in a nursing home. Surgeons had already drilled through his skull and mounted electrodes on his brain, the last card medicine had to play. It freed him from the bed and gave him little else back. So he signed the papers. While he waited for the date, he found a researcher at the University of Zurich testing an unusual protocol: ibogaine, the West African psychedelic famous for interrupting opioid addiction in one flood dose, given instead in small rising daily doses over four weeks. Four weeks later he left the nursing home and moved into an apartment with his mother. His motor control returned. He rides a bicycle three miles a day. Bryan Hubbard told me his story on my podcast last year. Bryan ran Kentucky's opioid commission until he proposed putting $42 million into ibogaine trials, and the state pushed him out. Texas picked up the idea and put $50 million behind it. He calls ibogaine "the most sophisticated medication on the planet." For a year, I filed his story where skeptics would: this being one remarkable case, a miracle even. Anecdotes stay anecdotes until someone publishes a mechanism. This week, Psychology Today published the mechanism. Psychology Today is not a psychedelic journal. It is the magazine in your therapist's waiting room, and it just ran a piece by Ohio State neuroscientist Gary Wenk on the newest finding: ibogaine switches on the genes and proteins that rebuild myelin. Myelin is the white insulation wrapped around the brain's wiring. Every thought you have travels across it. Multiple sclerosis strips it away. Long-term opioid use strips it too, methadone included. And nothing on the pharmacy shelf rebuilds it. This is where ibogaine stands alone. Psilocybin works mainly through one lever, the serotonin 2A receptor, and it does what it best does: grow new connections between neurons. Ibogaine hits glutamate, serotonin, sigma, and nicotinic receptors at once, raises growth factors that keep neurons alive, and turns on the machinery of myelin repair. Psilocybin renovates the brain's wiring diagram. Ibogaine re-insulates the wires themselves. It's why ibogaine keeps showing up where no other psychedelic works: a single dose cut PTSD, depression, and anxiety by more than 80 percent in Stanford's 30 Special Forces veterans with traumatic brain injury. About 50 Parkinson's patients have gone through the Zurich protocol. Roughly half improved, mostly those with the genetic form of the disease. Ibogaine does strain the heart, so nobody should go near it outside medical supervision. Half is not a miracle. Half is a signal, and clinical trials turn signals into answers. Ibogaine is still Schedule I in the United States, meaning there's no currently accepted medical use. Tell that to the man on the bicycle. psychologytoday.com/us/blog/…